The findings demonstrate that the peritoneal administration of both wild-type (WT) and genetically modified adipose-derived mesenchymal stem cells (ASCs) expressing CXCR4 and IL-10 is an effective and safe therapy in this mouse peritonitis model. The gene discussed is CXCR4; the disease is peritonitis.